While one mechanism does not exclude others and they might all play a role in different circumstances, the possibility of alternative pathways driving inflammation in IBD may provide insight into why medications targeting molecules different from TNF might be effective in SLR and PNR. The gene discussed is TNF; the disease is inflammatory bowel disease.